Dr. Greg Dietsch came to Mavupharma after serving as vice president of research at VentiRx Pharmaceuticals, an immuno-oncology company focused on the clinical development of Toll-like receptor (TLR) agonists for the treatment of cancer. Prior to joining VentiRx, Dr. Dietsch held multiple positions of increasing responsibilities at ICOS Corporation. In his role as vice president of preclinical sciences, he directed the ICOS pharmacology, drug metabolism, pathology and toxicology departments that supported both research and clinical development programs.
Dr. Dietsch has over 25 years industry experience in discovery research, translational biology, safety assessment and the clinical development of novel therapeutic agents. He has worked on programs in multiple therapeutic areas that include: multiple sclerosis, psoriasis, pulmonary arterial hypertension, chronic obstructive pulmonary disease, acute respiratory distress syndrome, oncology, immune-oncology, stroke, pancreatitis, sepsis, interstitial cystitis, erectile dysfunction and pain. Dr. Dietsch has advanced more than twenty therapeutic agents, including monoclonal antibodies, recombinant proteins, natural products and traditional small molecule drugs, from research/discovery into clinical development. Four of these programs lead to marketed products that include: Cialis, Adcirca, Thelin and Zydelig.
Dr. Dietsch received B.S. and M.S. degrees from the department of microbiology at Washington State University. He subsequently trained as a cellular immunologist and received his Ph.D. in microbiology/immunology from the Oregon Health Sciences University. Additionally, he trained as a toxicologist, and is an active Diplomat of the American Board of Toxicology.